Levosimendan not checked
Orion Corporation, Orion Pharma · ODM-109
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
6 active
12 in total · 8 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion”In the company’s words, NCT03541603 on ClinicalTrials.gov
- Tested for
- Amyotrophic Lateral Sclerosis (2 trials), Heart Failure With Normal Ejection Fraction (2 trials), Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction
- Main trialPhase 3
- “This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale. In this randomized, double-blind, placebo-controlled, parallel-group, multicenter study, subjects are allocated in a 2:1 ratio to receive either levosimendan (1 -2 mg daily) or placebo for 48 weeks. The primary endpoint is slow vital capacity (SVC) at 12 weeks, with the impact on patient function assessed through 48 weeks, adjusted for patient outcome, using ALSFRS-R (combined assessment of…”In the company’s words, NCT03505021 on ClinicalTrials.gov
- Other names
- ODM-109
Other drugs for Amyotrophic Lateral Sclerosis
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 23 Jul 2020 | Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | |
| Phase 3Terminated | 18 Nov 2020 | Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension | |
| Phase 2Completed | 7 Apr 2020 | Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF | |
| Phase 2Completed | 25 Apr 2023 | Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients | |
| Phase 2Ended | not given | Effects of Levosimendan in patients being weaned from venoarterial extracorporal membrane oxygenation. A randomized controlled investigator driven phase II trial | |
| Phase 3Authorised | not given | Effect of early use of levosimendan versus placebo on top of a conventional strategy of inotrope use on a combined morbidity-mortality endpoint in patients with cardiogenic shock. LevoHeartShock | |
| Phase 2Authorised | not given | LEVOSAH - Pilot study comparing the effectiveness of adding treatment with Levosimendan to usual care for the management of the acute phase of aneurysmal subarachnoid hemorrhages | |
| Phase 3Ended | not given | A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome (LevoTako Trial) | |
| Phase 3Authorised | not given | LEONARD. Levosimendan vs. Placebo Before Isolated Tricuspid Valve Surgery | |
| Phase 2Authorised | not given | Levosimendan in Cardiac Arrest: A Randomized Double-blinded Clinical Phase II Trial (LeICA) | |
| Phase 4Authorised | not given | Shorter weaning from invasive ventilation with levosimendan: a randomized, double-blind, multicenter study in critically ill patients. | |
| Phase 3/4Authorised | not given | LEVOMEMS: Comparison of the Hemodynamic Profile of Dobutamine and Levosimendan in the Current Therapeutic Context |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026